{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:40:38Z","timestamp":1793115638998,"version":"4.5.0"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,11,12]],"date-time":"2008-11-12T00:00:00Z","timestamp":1226448000000},"content-version":"vor","delay-in-days":6982,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Develop Med Child Neuro"],"published-print":{"date-parts":[[1989,10]]},"abstract":"<jats:sec><jats:title>SUMMARY<\/jats:title><jats:p>One hundred and eighty\u2010six consecutive children aged between six and 72 months admitted to the Manchester Children's Hospitals with a febrile convulsion in the first year of life, a complicated febrile convulsion, or more than one febrile convulsion within two years, were allocated randomly to one of three groups who were offered rectal diazepam in the event of a subsequent prolonged febrile convulsion, or prophylactic treatment with sodium valproate or phenobarbitone. Over\u2010all risk of recurrence was 30 per cent and adequate prophylaxic treatment did not lessen this risk. Side\u2010effects in 24 per cent of the valproate group and 61 per cent of the phenobarbitone group did not justify the use of prophylactic treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>R\u00c9SUM\u00c9<\/jats:title><jats:p>Indications du traitement des convulsions hyperthermiques par le diazepam rectal, le valproate ou le ph\u00e9nobarbital<\/jats:p><jats:p>Cent quatre\u2010vingt six enfants \u00e2g\u00e9s de six \u00e0 72 mois, admis cons\u00e9cutivement dans les h\u00f4pitaux d'enfants de Manchester pour convulsions hyperthermiques durant la premi\u00e8re ann\u00e9e de vie, convulsions f\u00e9briles compliqu\u00e9es, ou plus de trois convulsions hyperthermiques avant deux ans, ont \u00e9t\u00e9 r\u00e9partie au hasard dans l'un de trois groupes, b\u00e9n\u00e9ficiant soit uniquement de diazepam rectal en cas de convulsions f\u00e9briles prolong\u00e9es ult\u00e9rieure, soit d'un traitement pr\u00e9ventif par valproate de sodium ou ph\u00e9nobarbital. Le risque global de r\u00e9currence fut de 30 pour cent, non abaiss\u00e9 par un traitement prophylactique ad\u00e9quat. Les effets secondaires s'observant dans 24 pour cent des cas trait\u00e9s par valproate et 61 pour cent des ces trait\u00e9s par ph\u00e9nobarbital, le traitement prophylactique n'apparait pas justifi\u00e9.<\/jats:p><\/jats:sec><jats:sec><jats:title>ZUSAMMENFASSUNG<\/jats:title><jats:p>Intention, Fieberkr\u00e1mpfe rektal mit Diazepam, oder mit Valproat oder Phenobarbital zu behandeln<\/jats:p><jats:p>186 Kinder im Alter zwischen sechs und 72 Monaten, die wegen eines Fieberkrampfes im ersten Lebensjahr, eines Fieberkrampfes mit Komplikationen oder mit mehr als einem Fieberkrampf innerhalb von zwei Jahren im Manchester Children's Hospital aufgenommen wurden, wurden zuf\u00e4llig einer von drei Gruppen zugeteilt, die im Falle eines l\u00e4nger andauernden Fieberkrampfes rektal Diazepam bekamen oder prophylaktisch mit Sodiumvalproat oder Phenobarbital behandelt wurden. Insgesamt betrug das Rezidivrisiko 30 Prozent und eine entsprechende prophylaktische Behandlung konnte dieses Risiko nicht verringern. Die Nebenwirkungen bei 24 Prozent in der Valproat Gruppe und bei 61 Prozent in der Phenobarbital Gruppe sprechen gegen eine prophylaktische Therapie.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESUMEN<\/jats:title><jats:p>Intenci\u00f3n de tratar las convulsiones febriles con diazepam rectal, valproato o fenobarbital<\/jats:p><jats:p>Ciento ochenta y seis ni\u00f1os consecutivos de seis a 72 meses de edad ingresados en el Hospital Infantil de Manchester con una convulsi\u00f3n febril en el primer a\u00f1o de la vida, una convulsi\u00f3n febril complicada o m\u00e1s de una convulsi\u00f3n febril en el curso de dos a\u00f1os, fueron colocados al azar en uno de tres grupos a los que se ofrecia diazepam rectal en el caso de una nueva convulsi\u00f3n febril o se hac\u00eda un tratamiento profil\u00e1ctico con valproato s\u00f3dico o fenobarbital. El riesgo total de recurrencia fue del 30 por ciento y un adecuado tratamiento profil\u00e1ctico no disminuyo este riesgo. Los efectos secundarios en el 24 por ciento del grupo valproato y el 61 por ciento en el grupo fenobarbital no justificaron la utilizati\u00f3n de un tratamiento profil\u00e1ctico.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1469-8749.1989.tb04047.x","type":"journal-article","created":{"date-parts":[[2010,7,15]],"date-time":"2010-07-15T11:54:39Z","timestamp":1279194879000},"page":"617-625","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["INTENTION TO TREAT FEBRILE CONVULSIONS WITH RECTAL DIAZEPAM, VALPROATE OR PHENOBARBITONE"],"prefix":"10.1111","volume":"31","author":[{"given":"Ian","family":"McKinlay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,12]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198702263160901"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)92742-2"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92100-3"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1975.tb04746.x"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1982.tb13651.x"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1972.tb05262.x"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6009.559"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.54.11.855"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.60.11.1045"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.53.8.660"},{"key":"e_1_2_1_12_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00441308","article-title":"\u2018Sodium valproate versus phenobarbital in the prophylactic treatment of febrile convulsions in childhood.\u2019","volume":"137","author":"Lee K.","year":"1981","journal-title":"European Journal of Pediatrics"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(47)80139-8"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.292.6522.716"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.281.6235.277"},{"key":"e_1_2_1_16_1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1542\/peds.61.5.720","article-title":"\u2018Prognosis in children with febrile seizures.\u2019","volume":"61","author":"Nelson K. B.","year":"1978","journal-title":"Pediatrics"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.63.10.1189"},{"key":"e_1_2_1_18_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1469-8749.1988.tb14570.x","article-title":"\u2018Subsequent management of children with febrile convulsions.\u2019","volume":"30","author":"McKinlay I.","year":"1988","journal-title":"Developmental Medicine and Child Neurology"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.55.3.171"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6209.207"},{"key":"e_1_2_1_21_1","volume-title":"Clinical Trials.","author":"Schwartz D.","year":"1980"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.52.11.844"},{"key":"e_1_2_1_23_1","first-page":"67","article-title":"\u2018A controlled study of prophylactic long term treatment of febrile convulsions.\u2019","volume":"60","author":"Thorn I.","year":"1975","journal-title":"Acta Paediatrica Scandinavica"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.290.6478.1307"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6211.353"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/000992287901800710"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1977.tb07951.x"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1974.tb04942.x"}],"container-title":["Developmental Medicine &amp; Child Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1469-8749.1989.tb04047.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1469-8749.1989.tb04047.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T10:08:56Z","timestamp":1711620536000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1469-8749.1989.tb04047.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1989,10]]}},"alternative-id":["10.1111\/j.1469-8749.1989.tb04047.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-8749.1989.tb04047.x","archive":["Portico"],"relation":{},"ISSN":["0012-1622","1469-8749"],"issn-type":[{"value":"0012-1622","type":"print"},{"value":"1469-8749","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,10]]},"assertion":[{"value":"2008-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}